Keyphrases
AIDS/HIV
100%
Hepatitis C
100%
Health-related Quality of Life
100%
Sofosbuvir
100%
Daclatasvir
80%
Co-infected Patients
60%
Non-smoking
40%
Smoking Status
40%
WHOQOL
40%
Jakarta
20%
Positive Impact
20%
HCV RNA
20%
Non-associated
20%
Short Form 36 (SF-36)
20%
Predictive Factors
20%
Treatment Efficacy
20%
General Health
20%
Normal Body Mass Index
20%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
20%
Personal Beliefs
20%
SF-36 Questionnaire
20%
Fibrosis Stage
20%
Active Smokers
20%
Life Studies
20%
Non-cirrhosis
20%
Treatment Completion
20%
Quality of Life Domains
20%
SVR12
20%
Health Perception
20%
Life Transformation
20%
Level of Independence
20%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Hepatitis C
100%
Quality of Life
100%
Sofosbuvir
100%
Daclatasvir
57%
Short Form 36
28%
Liver Cirrhosis
14%
Body Mass Index
14%
Smoking
14%
Prospective Study
14%
Fibrosis
14%
Nonnucleoside Reverse Transcriptase Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Hepatitis C
100%
Sofosbuvir
100%
Daclatasvir
57%
Liver Cirrhosis
14%
Prospective Study
14%
Fibrosis
14%
Nonnucleoside Reverse Transcriptase Inhibitor
14%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Hepatitis C
100%
Sofosbuvir
100%
Daclatasvir
57%
Body Mass
14%
Neuroscience
Human Immunodeficiency Virus
100%
Hepatitis C
100%
Sofosbuvir
100%
Daclatasvir
57%
Body Mass Index
14%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus
100%
RNA
14%
Prospective Study
14%
Body Mass
14%
Smoking
14%